Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2006 1
2008 1
2009 1
2010 1
2011 2
2012 2
2013 3
2014 1
2015 1
2017 1
2020 1
2021 3
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Antimicrobial Strategies for Cystic Fibrosis.
Møller R, Pressler T, Qvist T. Møller R, et al. Among authors: pressler t. Semin Respir Crit Care Med. 2023 Apr;44(2):297-306. doi: 10.1055/s-0042-1758733. Epub 2022 Dec 19. Semin Respir Crit Care Med. 2023. PMID: 36535665
While many different strategies may be applied, rigorous microbiological surveillance, intensive eradication therapy, and long-term maintenance therapy based on inhaled antibiotics may be considered the main strategy for infection control in individuals with CF. ...
While many different strategies may be applied, rigorous microbiological surveillance, intensive eradication therapy, and long-term m …
Long-term amikacin liposome inhalation suspension in cystic fibrosis patients with chronic P. aeruginosa infection.
Bilton D, Fajac I, Pressler T, Clancy JP, Sands D, Minic P, Cipolli M, Galeva I, Solé A, Quittner AL, Jumadilova Z, Ciesielska M, Konstan MW; CLEAR-110 Study Group. Bilton D, et al. Among authors: pressler t. J Cyst Fibros. 2021 Nov;20(6):1010-1017. doi: 10.1016/j.jcf.2021.05.013. Epub 2021 Jun 16. J Cyst Fibros. 2021. PMID: 34144923 Free PMC article. Clinical Trial.
The CLEAR-110 extension study (ClinicalTrials.gov: NCT01316276; EudraCT: 2011-000443-24) assessed long-term safety, tolerability, and efficacy of ALIS in eligible patients who completed CLEAR-108. ...Mean change from baseline in sputum density of P. aeruginosa at day 672 w …
The CLEAR-110 extension study (ClinicalTrials.gov: NCT01316276; EudraCT: 2011-000443-24) assessed long-term safety, tolerability, and …
Bacterial persisters in long-term infection: Emergence and fitness in a complex host environment.
Bartell JA, Cameron DR, Mojsoska B, Haagensen JAJ, Pressler T, Sommer LM, Lewis K, Molin S, Johansen HK. Bartell JA, et al. Among authors: pressler t. PLoS Pathog. 2020 Dec 14;16(12):e1009112. doi: 10.1371/journal.ppat.1009112. eCollection 2020 Dec. PLoS Pathog. 2020. PMID: 33315938 Free PMC article.
In sum, the Hip phenotype appears to substantially contribute to long-term establishment of a lineage in the CF lung environment. Our results argue against the existence of a single dominant molecular mechanism underlying bacterial antibiotic persistence. ...
In sum, the Hip phenotype appears to substantially contribute to long-term establishment of a lineage in the CF lung environment. Our …
Withdrawal of dornase alfa increases ventilation inhomogeneity in children with cystic fibrosis.
Voldby C, Green K, Philipsen L, Sandvik RM, Skov M, Buchvald F, Pressler T, Nielsen KG. Voldby C, et al. Among authors: pressler t. J Cyst Fibros. 2021 Nov;20(6):949-956. doi: 10.1016/j.jcf.2021.02.004. Epub 2021 Feb 19. J Cyst Fibros. 2021. PMID: 33619014 Free article. Clinical Trial.
Hence, adherence to dornase alfa optimally needs to be addressed when using LCI and spirometric parameters as endpoints, even in short-term clinical trials....
Hence, adherence to dornase alfa optimally needs to be addressed when using LCI and spirometric parameters as endpoints, even in short-te …
Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.
Flume PA, Biner RF, Downey DG, Brown C, Jain M, Fischer R, De Boeck K, Sawicki GS, Chang P, Paz-Diaz H, Rubin JL, Yang Y, Hu X, Pasta DJ, Millar SJ, Campbell D, Wang X, Ahluwalia N, Owen CA, Wainwright CE; VX14-661-110 study group. Flume PA, et al. Lancet Respir Med. 2021 Jul;9(7):733-746. doi: 10.1016/S2213-2600(20)30510-5. Epub 2021 Feb 10. Lancet Respir Med. 2021. PMID: 33581080
Here, we present results of study 661-110 (EXTEND), a 96-week open-label extension study that assessed long-term safety, tolerability, and efficacy of tezacaftor-ivacaftor in participants aged 12 years or older with cystic fibrosis who were homozygous or heterozygous for t …
Here, we present results of study 661-110 (EXTEND), a 96-week open-label extension study that assessed long-term safety, tolerability …
Long-term outcome of lung transplantation for cystic fibrosis--Danish results.
Bech B, Pressler T, Iversen M, Carlsen J, Milman N, Eliasen K, Perko M, Arendrup H. Bech B, et al. Among authors: pressler t. Eur J Cardiothorac Surg. 2004 Dec;26(6):1180-6. doi: 10.1016/j.ejcts.2004.08.015. Eur J Cardiothorac Surg. 2004. PMID: 15541981
Burkholderia multivorans was present in three patients pre-transplant with satisfying long-term outcome in one patient. CONCLUSIONS: Lung transplantation is a well-established life-extending treatment for patients with CF and end-stage lung disease. The operative mortality …
Burkholderia multivorans was present in three patients pre-transplant with satisfying long-term outcome in one patient. CONCLUSIONS: …
The effect of short-term, high-dose oral N-acetylcysteine treatment on oxidative stress markers in cystic fibrosis patients with chronic P. aeruginosa infection -- a pilot study.
Skov M, Pressler T, Lykkesfeldt J, Poulsen HE, Jensen PØ, Johansen HK, Qvist T, Kræmer D, Høiby N, Ciofu O. Skov M, et al. Among authors: pressler t. J Cyst Fibros. 2015 Mar;14(2):211-8. doi: 10.1016/j.jcf.2014.09.015. Epub 2014 Oct 23. J Cyst Fibros. 2015. PMID: 25458464 Free article. Clinical Trial.
Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis.
Knudsen KB, Pressler T, Mortensen LH, Jarden M, Boisen KA, Skov M, Quittner AL, Katzenstein TL. Knudsen KB, et al. Among authors: pressler t. Patient Prefer Adherence. 2017 Sep 21;11:1613-1623. doi: 10.2147/PPA.S141267. eCollection 2017. Patient Prefer Adherence. 2017. PMID: 29033550 Free PMC article.
However, several studies have demonstrated that many young adults with CF report mental health problems and poor adherence to their prescribed treatments, challenging their long-term physical health. Treatment guidelines recommend interventions to improve adherence and sel …
However, several studies have demonstrated that many young adults with CF report mental health problems and poor adherence to their prescrib …
Long-term, low-dose azithromycin treatment reduces the incidence but increases macrolide resistance in Staphylococcus aureus in Danish CF patients.
Hansen CR, Pressler T, Hoiby N, Johansen HK. Hansen CR, et al. Among authors: pressler t. J Cyst Fibros. 2009 Jan;8(1):58-62. doi: 10.1016/j.jcf.2008.09.001. Epub 2008 Oct 11. J Cyst Fibros. 2009. PMID: 18849202 Free article.
BACKGROUND: Since 2001, long-term, low-dose azithromycin treatment has been used for CF patients chronically infected with Pseudomonas aeruginosa in the Copenhagen CF centre. ...No macrolide resistance was found in H. influenzae or S. pneumoniae. CONCLUSION: Long-term …
BACKGROUND: Since 2001, long-term, low-dose azithromycin treatment has been used for CF patients chronically infected with Pseudomona …
Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study.
Hansen CR, Pressler T, Koch C, Høiby N. Hansen CR, et al. Among authors: pressler t. J Cyst Fibros. 2005 Mar;4(1):35-40. doi: 10.1016/j.jcf.2004.09.001. J Cyst Fibros. 2005. PMID: 15752679 Free article.
Macrolides can increase lung function and weight in patients, and reduce exacerbations. METHODS: In 2001, we introduced long-term, low-dose azithromycin (AZ) treatment as an integral part of our routine treatment of these patients. ...Median CRP decreased from 6.2 mmol/l t …
Macrolides can increase lung function and weight in patients, and reduce exacerbations. METHODS: In 2001, we introduced long-term, lo …
18 results